Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations

JM Aguado, JT Silva, M Fernández-Ruiz… - Transplantation …, 2018 - Elsevier
Solid organ transplant (SOT) recipients are especially at risk of developing infections by
multidrug resistant (MDR) Gram-negative bacilli (GNB), as they are frequently exposed to …

Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii

S Zhang, L Di, Y Qi, X Qian, S Wang - Frontiers in Cellular and …, 2024 - frontiersin.org
Patients with severe carbapenem-resistant Acinetobacter baumannii (CRAB) infections
currently face significant treatment challenges. When patients display signs of infection and …

Task force on management and prevention of Acinetobacter baumannii infections in the ICU

J Garnacho-Montero, G Dimopoulos, G Poulakou… - Intensive care …, 2015 - Springer
Introduction Acinetobacter baumannii constitutes a dreadful problem in many ICUs
worldwide. The very limited therapeutic options available for these organisms are a matter of …

Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia

J Garnacho-Montero, R Amaya-Villar… - Expert review of anti …, 2015 - Taylor & Francis
Carbapenem-resistant Acinetobacter baumannii (CRAB) constitutes an increasing problem
worldwide. CRAB bacteremia is associated with a high fatality rate and its optimal treatment …

Clinical relevance of in vitro synergistic activity of antibiotics for multidrug-resistant Gram-negative infections: A systematic review

KZ Vardakas, F Athanassaki, V Pitiriga… - Journal of Global …, 2019 - Elsevier
Objectives The aim of this review was to investigate the outcomes of patients infected with
multidrug-resistant (MDR) or extensively drug-resistant (XDR) Gram-negative bacteria …

In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates

DJ Hong, JO Kim, H Lee, EJ Yoon, SH Jeong… - … and infectious disease, 2016 - Elsevier
Increased use of colistin in a clinical setting had resulted in the emergence of colistin-
resistant (CoR) Acinetobacter baumannii. Combination therapy has been studied as a new …

Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections

E Wenzler, DA Goff, R Humphries… - Infectious Diseases and …, 2017 - Springer
Acinetobacter remains one of the most challenging pathogens in the field of infectious
diseases owing primarily to the uniqueness and multiplicity of its resistance mechanisms …

Advances in the clinical treatment of multidrug-resistant pathogens using polymyxins

Y Huang, M Liao, X Hu, H Hu… - Journal of Antimicrobial …, 2024 - academic.oup.com
Objectives Polymyxins are a vital class of antibiotics used to combat multidrug-resistant
Gram-negative bacteria. However, their use is limited due to potential nephrotoxicity and the …

In-Vitro Evaluation of Different Antimicrobial Combinations with and without Colistin Against Carbapenem-Resistant Acinetobacter Baumannii

A Oliva, S Garzoli, M De Angelis, C Marzuillo, V Vullo… - Molecules, 2019 - mdpi.com
Carbapenem-resistant Acinetobacter baumannii (CR-Ab) infections are associated with high
morbidity and mortality. The aim of the study was to evaluate the in-vitro activity of different …

多重耐药鲍曼不动杆菌治疗药物研究进展

叶有娣, 谢家政 - 中国临床药理学与治疗学, 2016 - manu41.magtech.com.cn
多重耐药鲍曼不动杆菌治疗药物研究进展 欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天
是 分享到: 公众号 订阅号 高级检索 图表检索 首页 期刊介绍 编委会 投稿须知 期刊订阅 在线期刊 …